Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX629 in Patients With Chronic Cough
| ALDX Stock | USD 5.37 0.08 1.51% |
Slightly above 51% of Aldeyra's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Aldeyra suggests that some traders are interested. Aldeyra's investing sentiment can be driven by a variety of factors including economic data, Aldeyra's earnings reports, geopolitical events, and overall market trends.
Aldeyra |
LEXINGTON, Mass., June 27, 2023 Aldeyra Therapeutics, Inc. , a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line results from the Phase 2 clinical trial of orally administered ADX629, an investigational new drug, in patients with chronic cough. The clinical trial demonstrated statistically significant reduction in cough frequency following administration of ADX6
Read at finance.yahoo.com
 |
Aldeyra Fundamental Analysis
We analyze Aldeyra's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aldeyra using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aldeyra based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Aldeyra is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Aldeyra Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aldeyra stock to make a market-neutral strategy. Peer analysis of Aldeyra could also be used in its relative valuation, which is a method of valuing Aldeyra by comparing valuation metrics with similar companies.
Peers
Aldeyra Related Equities
| LXRX | Lexicon Pharmaceuticals | 21.92 | ||||
| XFOR | X4 Pharmaceuticals | 13.43 | ||||
| LYRA | Lyra Therapeutics | 5.00 | ||||
| TARS | Tarsus Pharmaceuticals | 2.94 | ||||
| ETON | Eton Pharmaceuticals | 0.58 | ||||
| ETNB | 89bio | 0.50 | ||||
| CGEM | Cullinan Oncology | 0.24 | ||||
| TVTX | Travere Therapeutics | 0.37 | ||||
| DAWN | Day One | 0.45 | ||||
| INZY | Inozyme Pharma | 0.67 | ||||
| BPMC | Blueprint Medicines | 0.96 | ||||
| GPCR | Structure Therapeutics | 1.30 | ||||
| VRDN | Viridian Therapeutics | 1.96 | ||||
| TERN | Terns Pharmaceuticals | 3.18 | ||||
| MCRB | Seres Therapeutics | 3.23 | ||||
| IBRX | Immunitybio | 3.33 | ||||
| PHAT | Phathom Pharmaceuticals | 3.88 | ||||
| BLRX | BioLineRx | 4.00 | ||||
| ARDX | Ardelyx | 7.87 | ||||
| HOOK | Hookipa Pharma | 7.88 |
Additional Tools for Aldeyra Stock Analysis
When running Aldeyra's price analysis, check to measure Aldeyra's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra is operating at the current time. Most of Aldeyra's value examination focuses on studying past and present price action to predict the probability of Aldeyra's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aldeyra's price. Additionally, you may evaluate how the addition of Aldeyra to your portfolios can decrease your overall portfolio volatility.